Our Mission
With A.I., We improve human life

Infervision is a leading AI medical technology company established in 2016. With a focus on improving multi-disciplinary services and operations with AI, Infervision helps healthcare providers in three key areas: disease screening and diagnosis, patient treatment and management, research and development.

Adopting a vertical and horizontal product strategy, Infervision offers a comprehensive series of AI-assisted software to detect a wide range of anomalies such as cancers, infectious diseases, cardiovascular diseases, cerebrovascular diseases and trauma and more. Alongside existing disease screening and diagnosis (InferRead®), intervention and treatment (InferOperate®), patient health management (InferCare®), and teaching and research initiatives (InferScholar®, InferMartrix, InferEducate), Infervision is the trusted partner for hospitals, other medical institutions, governments, doctors and patients across the globe.

Our Journey


Infervision founded
Angel financing completed

Series A and B financing completed

Recognized as National High-Tech Company



US, Europe and Japan offices established
Series B+ and C financing completed  

AI going overseas: Participate in world-renowned radiology conferences (ECR, CCR, RSNA, etc.)



Fight against COVID-19 pandemic with AI technology

Four main marketing approvals: CE, PMDA, FDA, NMPA

InferRead® CT Stroke received 510(k) clearance from the FDA

Product procured by the European Commission, and included in the medical devices ordering list under the Global Drug Facility (GDF) hosted by the United Nations Office for Project Services (UNOPS)



InferRead® CT Fracture and InferRead® CT Stroke received the NMPA Class III medical device registration

Product selected into procurement list of NHS  

InferRead® CT Target Reconstruction, InferRead® CTA Coronary, and InferOperate® Thorax Planning received NMPA Class III medical device registration

InferRead® DR Chest received MDR CE and UKCA marking  
Product procured by the UN to East Europe and Central Asia



Partnered with SimonMed, one of the largest outpatient medical imaging providers in the US

InferOperate® Liver Planning and Urology Planning received NMPA Class lll medical device registration

To be continued…
Subscribe to know first

Receive monthly news and insights in your inbox. Don't miss out!

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
20-22 Wenlock Road,
London, N1 7GU, UK
Mainzer Str. 75,
Wiesbaden, 65189, Germany
1099 Wall St W, Lyndhurst,
New Jersey